These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27311520)

  • 1. Level of Blood Pressure Control and Cardiovascular Events: SPRINT Criteria Versus the 2014 Hypertension Recommendations.
    Ko MJ; Jo AJ; Park CM; Kim HJ; Kim YJ; Park DW
    J Am Coll Cardiol; 2016 Jun; 67(24):2821-31. PubMed ID: 27311520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Hypertension: Which Goal for Which Patient?
    Jarraya F
    Adv Exp Med Biol; 2017; 956():117-127. PubMed ID: 27722961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
    Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
    Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials.
    Brouwer TF; Vehmeijer JT; Kalkman DN; Berger WR; van den Born BH; Peters RJ; Knops RE
    Diabetes Care; 2018 Jun; 41(6):1142-1148. PubMed ID: 29212825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Optimal Diastolic Blood Pressure Range Among Adults With Treated Systolic Blood Pressure Less Than 130 mm Hg.
    Li J; Somers VK; Gao X; Chen Z; Ju J; Lin Q; Mohamed EA; Karim S; Xu H; Zhang L
    JAMA Netw Open; 2021 Feb; 4(2):e2037554. PubMed ID: 33595663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
    Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
    Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial).
    Patel KK; Arnold SV; Chan PS; Tang Y; Pokharel Y; Jones PG; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28373269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups: Age <50 Years, Diabetes Mellitus, or a History of Stroke.
    Bress AP; Tanner RM; Hess R; Gidding SS; Colantonio LD; Shimbo D; Muntner P
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27405811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The SPRINT Research. A Randomized Trial of Intensive versus Standard Blood-Pressure Control].
    Widimský J
    Vnitr Lek; 2016 Jan; 62(1):44-7. PubMed ID: 26967236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Cardiovascular Disease Events Prevented with Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline.
    Bress AP; Colantonio LD; Cooper RS; Kramer H; Booth JN; Odden MC; Bibbins-Domingo K; Shimbo D; Whelton PK; Levitan EB; Howard G; Bellows BK; Kleindorfer D; Safford MM; Muntner P; Moran AE
    Circulation; 2019 Jan; 139(1):24-36. PubMed ID: 30586736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood pressure level associated with lowest cardiovascular event in hypertensive diabetic patients.
    Lee CJ; Hwang J; Lee YH; Oh J; Lee SH; Kang SM; Choi D; Kim HC; Park S
    J Hypertens; 2018 Dec; 36(12):2434-2443. PubMed ID: 30015754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical application and potential effects of 2014 hypertension guidelines on incident cardiovascular events.
    Ko MJ; Park CM; Kim YJ; Kang SH; Park DW
    Am Heart J; 2015 Nov; 170(5):1042-1049.e5. PubMed ID: 26542515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
    Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
    PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antihypertensive treatment in Asian populations: a meta-analysis of prospective randomized controlled studies (CARdiovascular protectioN group in Asia: CARNA).
    Yano Y; Briasoulis A; Bakris GL; Hoshide S; Wang JG; Shimada K; Kario K
    J Am Soc Hypertens; 2014 Feb; 8(2):103-16. PubMed ID: 24157055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines.
    Egan BM; Li J; Wagner CS
    Hypertension; 2016 Aug; 68(2):318-23. PubMed ID: 27354422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the 2014 expert panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.
    Borden WB; Maddox TM; Tang F; Rumsfeld JS; Oetgen WJ; Mullen JB; Spinler SA; Peterson ED; Masoudi FA
    J Am Coll Cardiol; 2014 Dec; 64(21):2196-203. PubMed ID: 25447261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Office Blood Pressure Range and Cardiovascular Events in Patients With Hypertension: A Nationwide Cohort Study in South Korea.
    Kwon CH; Kim W; Shin JH; Lee CJ; Kim HC; Kang SH; Jung MH; Kim DH; Lee JH; Kim HL; Kim HM; Cho IJ; Cho I; Kang DR; Lee HY; Chung WJ; Ihm SH; Kim KI; Cho EJ; Sohn IS; Park S; Shin J; Ryu SK; Kang SM; Cho MC; Kim JH; Lee JH; Kim JY; Pyun WB; Sung KC
    J Am Heart Assoc; 2021 Apr; 10(7):e017890. PubMed ID: 33739126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicability of the Systolic Blood Pressure Intervention Trial (SPRINT) to the Canadian Population.
    Leung AA; Chang HJ; McAlister FA; Khan NA; Rabi DM; Quan H; Padwal RS
    Can J Cardiol; 2018 May; 34(5):670-675. PubMed ID: 29731026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of baseline systolic blood pressure on the relationship between intensive blood pressure control and cardiovascular outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT).
    Sun X; Guo Y; Nie Z; Cheng J; Zhou H; Zhong X; Zhang S; Du Z; Zhuang X; Liao X
    Clin Res Cardiol; 2019 Mar; 108(3):273-281. PubMed ID: 30167807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Visit-to-Visit Variability in Systolic Blood Pressure on Cardiovascular Outcomes in Korean National Health Insurance Service-National Sample Cohort.
    Choi S; Shin J; Choi SY; Sung KC; Ihm SH; Kim KI; Kim YM
    Am J Hypertens; 2017 Jun; 30(6):577-586. PubMed ID: 28052880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.